Abstract A 28-year-old 
Introduction

Hypereosinophilic syndrome (HES) was first characterized in 1975 (1). At that time, the molecular mechanisms of HES had been unclarified, though those patients with clonal disorders were diagnosed as chronic eosinophilic leukemia (CEL). The first report of treatment of HES patients with imatinib mesylate (imatinib) was in 2001, and then some case reports and small case series followed; excellent effects were observed in a high proportion of the patients (2-4). In 2003, an epoch-making discovery was reported, in which a fusion of FIP1-like 1 gene (FIP1L1) to the platelet derived growth factor receptor α gene (PDGFRA) was formed, as a result of chromosome 4q12 interstitial deletion in HES patients with normal karyotype
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F I P 1 L 1 g e n e , a n d i n t h e e x o n 1 3 o f t h e P DGF R A g e n e a s p r ev i o u s l y r e p o r t e d ( 5 ) . Ar r o ws i n d i c a t e mu l t i p l e F / P f u s i o n mRNAs . L a n e 1 : 1 0 0 b p l a d d e r ma r k e r , L a n e 2 : n o r ma l i n d iv i d u a l , L a n e 3 : t h i s p a t i e n t . marked reduction of erythroblasts (Fig. 1C) (Fig. 1D) We further examined the detailed structure of the F/Pfusion mRNA. The RT-PCR products showed multiple bands in the agarose gel (Fig. 3) , and then each sequence was determined. The deduced DNA breakpoint of the FIP1L1 gene was assumed to be in intron 10, and the deduced DNA breakpoint of the PDGFRA gene was at 81 bp downstream from the first nucleotide in exon 12 (Fig. 4) To (Fig. 5) . These results confirmed that tyrosine kinase f o r 4 8 h r s , a n d t h e n t h e v i a b l e c e l l s  we r e c o u n t e d b y mi c r o s c o p e a f t e r t r y p a n b l u e s t a i n i n g . E a c h  b a r i n d i c a t e s t h e r e l a t i v e v i a b l e c e l l n u mb e r , i n wh i c h t h e c e l l  n u mb e r wi t h o u t a n y d r u g ( -) a r e s u p p o s e d t o b e 1 0 0 %. E a c h  a s s a y wa s d o n e i n t r i p l i c a t e , a n d me a n ± S D i s s h o wn . 
evaluate the effects of imatinib on the growth of the eosinophils, we performed a cell viability assay by trypan blue dye exclusion method (9). In addition to imatinib, PKC412 which is a staurosporine derivative possessing capability of inhibition of multiple kinases (10), 17-AAG was also used. Both imatinib and PKC412 decreased the viable cell counts by 60% and by 20%, respectively, whereas 17-AAG (as a negative control) did not decrease the viable cell count
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inhibitors such as imatinib and PKC412 actually exert inhibitory effects on the viability of the patient's eosinophils, in vitro.
Discussion
Since the discovery of the F/P-fusion gene (5) , a comprehensive picture has emerged regarding several characteristics of the fusion, its incidence, biological features, and the clinical profiles of the F/P-positive CEL patients (11) .
In the present patient, we performed a molecular analysis of the F/P fusion mRNAs. It seems unlikely that the RT-PCR products were pseudo-PCR products as a previous report warned (12) . We performed the RT-PCR for 50 hypereosinophilia patients and 2 normal individuals and among them, RT-PCR product was observed only in the present case, i.e., F/P-positive rate was 2% (1/50 (5, 12, 13) . Our results were also in accordance with previous reports that the DNA breakpoints in FIP1L1 gene were diverse but those in the PDGFRA gene were tightly clustered within the exon 12 (5, 12, 13) , indicating that interruption of the juxtamembrane domain of PDGFRα is indispensable for kinase activation in the context of F/P fusion protein (14) . The RT-PCR analysis of the F/P fusion mRNA in the present patient showed diversely-spliced transcripts. The pattern of the fusion mRNAs found in our patient was similar but not at all the same from those reported before (5, 12, 13) , and this diversity seems to be one of the characteristics of the F/P fusion mRNA.
From the clinical aspect of the present patient, the hema-tological response to imatinib was very rapid, as reported in the literature (15 (18, 19) . Other clinical studies of imatinib-treated F/Ppositive CEL have also been reported by some study groups (15, 20, 21 (23, 24) , though the mechanism of PRCA induced by IFN-α also remained unclear.
In conclusion, we have confirmed the long efficacy and good drug tolerance with a low dose of imatinib in the treatment of F/P-positive CEL patients. It is important to determine the optimal imatinib dose required to maintain the disease in molecular remission. Imatinib-induced PRCA is a rare event, but it is important to bare it in mind when severe anemia occurs during imatinib therapy.
